The Effect of Informative Letters on the Prescription and Receipt of Schedule II Controlled Substances
How to cite
Finkelstein, Amy; Yokum, David; Sacarny, Adam. 2014. "The Effect of Informative Letters on the Prescription and Receipt of Schedule II Controlled Substances." AEA RCT Registry. AEARCTR-0000525. https://doi.org/10.1257/rct.525-7.0
Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.
* Primary investigator
Abstract
Fraud and waste is estimated to cost the American health care system nearly $200 billion each year, and the public Medicare and Medicaid programs about $60 billion each year. This study will evaluate a new method for fighting fraud: mailing informative letters to outlier providers to notify them of their aberrant behavior. These letters are targeted at high prescribers of schedule II controlled substances in Medicare Part D. We will look at the effects of these letters on the behavior of providers and their patients. These effects are of substantial policy interest as they suggest how to best design anti-fraud policies. They are also of academic interest, shedding light on the behavior of physicians and their patients.
Intervention
A letter to outlier prescribers of schedule II controlled substances explaining that their prescribing behavior is highly unlike their peers.
Experimental design
An analysis was conducted to identify outlier prescribers of Schedule II controlled substances in the Medicare Part D. This analysis identified a group of prescribers, and they were then randomly allocated to a treatment or a control group.
Design details
Papers from this trial
- Sacarny, Adam, David Yokum, Amy Finkelstein, and Shantanu Agrawal. "Medicare Letters To Curb Overprescribing Of Controlled Substances Had No Detectable Effect On Providers." Health Affairs. 2016; 35(3); 471-479. doi:10.1377/hlthaff.2015.1025 http://content.healthaffairs.org/content/35/3/471
Cited by
No citation data available for this registration yet.